Amgen Data Breach: Biotechnology Giant Discloses Theft of Patient Health Data in Cloud Cyberattack
Amgen data breach headlines have put the biotechnology giant at the center of the healthcare industry’s escalating cybersecurity crisis. Amgen Inc. disclosed on July 31, [Read More…]
Novo Nordisk Ziltivekimab ZEUS Trial: Phase 3 Cardiovascular Readout Misses Primary MACE Reduction Target
Novo Nordisk has released headline results from the Phase 3 ZEUS cardiovascular outcomes trial evaluating monthly subcutaneous ziltivekimab in patients with ASCVD, CKD, and elevated systemic inflammation.
Roche Biocon Perjeta Lawsuit: Genentech Sues Over Biocon’s Breast-Cancer Biosimilar in New Jersey Court
Genentech and Roche have filed a new patent-infringement lawsuit against Biocon in New Jersey federal court, alleging Biocon’s proposed pertuzumab biosimilar infringes patents covering Perjeta, Roche’s blockbuster HER2-positive breast-cancer treatment, the second major U.S. action against Biocon over the same product in 2026.
Sanofi Q2 2026 Results: Dupixent Sales Growth Powers Record Second Quarter as Guidance is Upgraded
Sanofi posted 17.8% Q2 2026 sales growth at constant exchange rates, driven by Dupixent’s record €5.2 billion quarter and a 48.3% jump in pharma launches, prompting an upgraded full-year outlook.
IQVIA Q2 2026 Results: Revenue Climbs 8.7% to $4.37 Billion, Company Raises Full-Year 2026 Guidance
IQVIA Q2 2026 results show revenue up 8.7% to $4.368 billion, Adjusted EPS of $3.15, and a raised full-year 2026 outlook, driven by record R&D Solutions bookings and accelerating Commercial Solutions growth.
GSK Q2 2026 Results: Core Operating Profit Rises 7% as Specialty Medicines and Vaccines Drive Growth
GSK’s Q2 2026 results show core operating profit up 7% to £2.8 billion, driven by Specialty Medicines and Vaccines, alongside plans for 20+ Phase III trial starts and the $10.6bn Nuvalent acquisition.
AstraZeneca H1 2026 Results: Total Revenue Climbs to $30.7 Billion as Company Reaffirms $80 Billion 2030 Ambition
AstraZeneca’s H1 2026 results show Total Revenue climbing 9% to $30,672 million and Core EPS up 12% to $5.21, powered by Oncology and Rare Disease growth, 30 new regulatory approvals, and fresh licensing deals for Zegfrovy and TQC3721 — as the company reaffirms its $80 billion 2030 revenue ambition.
Sanofi Ends Amlitelimab Atopic Dermatitis Development, Will Not Seek Global Regulatory Approval
Sanofi has discontinued amlitelimab in moderate-to-severe atopic dermatitis and will not pursue global regulatory submissions, citing ESTUARY phase 3 data that did not show a meaningful edge over standard of care. Full-year 2026 guidance is unaffected.
Samsung Biologics Q2 2026 Earnings: Revenue Rises to KRW 1,321 Billion Amid Global Manufacturing Expansion
Samsung Biologics Q2 2026 earnings rose year-over-year to KRW 1,321 billion in revenue and KRW 586 billion in operating profit, as the CDMO advanced its Rockville facility integration, Plant 5 ramp-up, and pending PolyPeptide Group acquisition.
Danaher Corporation Q2 2026 Financial Results; Strategic Capital Allocation, and Market Valuation Dynamics
Danaher Corporation (NYSE: DHR) reported strong second-quarter 2026 financial results, generating revenue of $6.265 billion (+5.5% YoY) and non-GAAP adjusted diluted earnings per share (EPS) of $1.94 (+8.0% YoY), with both key metrics outperforming Wall Street consensus estimates. Non-GAAP core sales grew 3.0% overall and 4.5% when excluding post-pandemic respiratory testing normalizations, driven by a rebound across Life Sciences workflows and continued adoption of clinical diagnostics menus.